Vinci Mizranita


Combinations of HAART using 2 NRTIs plus NNRTIs or PIs (zidovudine, abacavir or tenofovir plus lamivudine, or emtricitabine plus tenofovir) are preferred treatment of HIV infection internationally and in Australia.Some antiretroviral should not be combined due to overlapping toxicities and potential viral antagonism (e.g. Atazanavir + indinavir, didanosine + stavudine). The challenges for treating HIV infection will be to reduce adverse effects, drug resistance, and increased options for treatment-experienced patients (HIV patient with previously treated using ARV).

Full Text:



Calmy, A., Petoumenos, K., Lewden, C., Law, M., Bocquentin, F., Hesse, K., Cooper, D., Carr, A., Bonnet, F., 2010. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts 171–180.

Chowers, M.Y., Gottesman, B.S., Leibovici, L., Pielmeier, U., Andreassen, S., Paul, M., 2009. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review 239–250. doi:10.1093/jac/dkp191

Chung, M.H., Kiarie, J.N., Barbra, A., Lehman, D.A., Overbaugh, J., Kinuthia, J., Njiri, F., John-stewart, G.C., 2010. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial 13, 799–807.

Egger, S., Petoumenos, K., Kamarulzaman, A., Hoy, J., Fracp, M., Sungkanuparph, S., Chuah, J., 2010. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD) 50, 513–520.

Falster, K., Gelgor, L., Shaik, A., Zablotska, I., Prestage, G., Grierson, J., Thorpe, R., Pitts, M., Anderson, J., Chuah, J., Mulhall, B., Petoumenos, K., Kelleher, A., Law, M.G., 2009. Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment 5, 141–154.

Geretti, A.M., Harrison, L., Green, H., Sabin, C., Hill, T., Fearnhill, E., Pillay, D., Dunn, D., Collaborative, U.K., Drug, H.I. V, 2009. Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy 48, 1296–1305. doi:10.1086/598502

Loutfy, MR., Ackad, N., Antoniou, T., Baril, J.G., Conway B., de Wet, J., et al, 2007. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen 8, 259–268.

Marrone, J., Fairley, C.K., Chen, M., Hocking, 2007. Comparisons of trends in antiretroviral use and HIV notification rates between three Australian states 31, 131-134.

Moore, D.M, Hogg, R.S., Yip, B., Wood, E., Harris, M., Montaner, J.S.G., 2006. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy 7, 311–316.

Musiime, V., Ssali, F., Kayiwa, J., Namala, W., Kizito, H., Kityo, C., Mugyenyi, P., 2009. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine 25, 989–996. doi:10.1089/aid.2009.0054

Simoni, J.M., Pearson, C.R., Pantalone, D.W., Marks, G., Crepaz, N., 2006. Efficacy of Interventions in Improving Highly Active Antiretroviral Therapy Adherence and HIV-1 RNA Viral Load 43.

Walmsley, S.L., Thorne, A., Loutfy, M.R., Lapierre, N., Macleod, J., Harrigan, R., Trottier, B., Conway, B., 2007. A Prospective Randomized Controlled Trial of Structured Treatment Interruption in HIV-Infected Patients Failing Highly Active Antiretroviral Therapy ( Canadian HIV Trials Network Study 164 ) 45, 418–425.

Zhou, J., Paton, N.I., Ditangco, R., Chen, Y., Kamarulzaman, A., Kumarasamy, N., Lee, C.K.C., Li, P.C.K., Merati, T.P., 2010. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database 8–16.


  • There are currently no refbacks.